July 23 (Reuters) - Precision BioSciences Inc DTIL.O:
PRECISION BIOSCIENCES RECEIVES FDA ORPHAN DRUG DESIGNATION FOR PBGENE-DMD FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
PRECISION BIOSCIENCES INC - CLINICAL DATA FOR PBGENE-DMD EXPECTED IN 2026
Source text: ID:nBw9GS74La
Further company coverage: DTIL.O
((Reuters.Briefs@thomsonreuters.com;))